[Skip to Navigation]
Sign In
Comment & Response
August 26, 2021

Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity

Author Affiliations
  • 1University of Ottawa, Ottawa, Ontario, Canada
JAMA Oncol. 2021;7(10):1577-1578. doi:10.1001/jamaoncol.2021.3338

To the Editor In their Original Investigation, Del Paggio et al1 state that progression-free survival (PFS) is an unreliable surrogate for overall survival (OS). Progression-free survival hazard ratio (HR) poorly predicts OS HR, and absolute gains in median PFS inaccurately predict OS gains.2 However, gain in PFS half-life is a good predictor of OS gain.2 For example, studies with low crossover with a PFS half-life gain of 4 or more months have an 84% probability of an OS gain of 5 or more months.2

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words